Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs ENSG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADUS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

ADUS Overall Winner 6-Pillar Tally: ADUS 4 – 2 ENSG Matrix Metrics: ADUS 7 – 3 ENSG

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over The Ensign Group, Inc. (ENSG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ENSG carries 48.3/100 (HOLD) at $176.32 (20.1x Forward P/E, 8.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs ENSG
ADUS NASDAQ Head-to-Head Winner
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
ENSG NASDAQ
The Ensign Group, Inc.
Services-Skilled Nursing Care Facilities
$176.32
-0.15% 1D
Market Cap $10.3B
TTM Revenue $5.67B
Forward P/E 20.1x
Beta / 30D Vol 0.12β · 42% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 45.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.5 · SMA20: $182.49 · SMA50: $177.52

6-Pillar Scorecard Institutional Category Breakdown (ADUS 4 – 2 ENSG)

Columns: Metric · ADUS · ENSG
1. Valuation Multiples ADUS
Forward P/E 16.1x 20.1x
Trailing P/E 20.1x 26.3x
PEG Ratio 1.05x 1.40x
EV / Revenue 1.5x 2.2x
2. Growth & Scale ENSG
Revenue Growth (YoY) +7.0% +14.5%
Earnings Growth (YoY) +24.2% +23.9%
TTM Revenue (USD) $1.50B $5.67B
Market Cap $2.3B $10.3B
3. Profitability & Quality ADUS
Gross Margin 32.3% 17.1%
Operating Margin 10.4% 8.8%
Net Profit Margin 7.4% 7.0%
Return on Equity (ROE) 10.0% 17.1%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $173M EBITDA $210M
Cash Flow Margin 11.5% EBITDA Mgn 3.7%
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $1.95B Net Debt (0.89x D/E)
Dividend Yield None (0.00%) 0.14%
5. Options & Positioning ENSG
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 21.9% (16th %ile) 99.5% (62nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 21.9% of Rev ($329M) 8.3% of Rev ($471M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (7) vs ENSG (3)
Institutional Metric ADUS ENSG Criterion Row Edge
Market Capitalization
Scale
$2.3B $10.3B Larger Scale ENSG
Trailing P/E Ratio
Valuation
20.1x 26.3x Lower Multiple ADUS
Forward P/E Ratio
Valuation
16.1x 20.1x Lower Multiple ADUS
Revenue Growth (YoY)
Growth
+7.0% +14.5% Higher Growth ENSG
Operating Margin (TTM)
Profitability
10.4% 8.8% Higher Margin ADUS
Net Profit Margin
Profitability
7.4% 7.0% Higher Margin ADUS
Return on Equity (ROE)
Capital Efficiency
10.0% 17.1% Higher ROE ENSG
52-Week Range Position
Momentum
79% ($88–$132) 46% ($142–$218) Stronger Trend ADUS
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.12β · 42% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $5.67B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 17.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev 1.40x PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $210M ($1.95B Net Debt (0.89x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADUS +1.0 pp
ADUS: -0.14% · ENSG: -1.14%
3M Horizon ADUS +3.09 pp
ADUS: +1.39% · ENSG: -1.7%
6M Horizon ADUS +29.67 pp
ADUS: +32.22% · ENSG: +2.55%
1Y Horizon ADUS +13.73 pp
ADUS: +12.39% · ENSG: -1.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs ENSG. Trailing 12-month operating profitability (ADUS 10.4% vs ENSG 8.8%) and valuation multiples (ADUS 16.1x vs ENSG 20.1x Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
ENSG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.67B
Gross Margin17.1%
Op. Margin8.8%
ROE / Fwd P/E17.1% · 20.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENSG CONSOLIDATION
73d in phase · OBV NEUTRAL
Current IV 99.5%
IV Percentile 62nd %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENSG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
ENSG Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $10.3B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 8.3% of Rev ($471M)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs ENSG Key Questions & Quantitative Answers

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over The Ensign Group, Inc. (ENSG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ENSG carries 48.3/100 (HOLD) at $176.32 (20.1x Forward P/E, 8.8% operating margin). Technically, ADUS sits in a Markup phase (RSI 51.6, UNCLASSIFIED options structure) and ENSG sits in a Neutral phase (RSI 43.5, CONSOLIDATION options structure).

ENSG leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with ENSG at +14.5% YoY revenue growth and +23.9% YoY earnings growth on $5.67B TTM revenue (17.1% gross margin, 8.8% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $5.67B for ENSG. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 8.3% of Rev ($471M) (0 disclosures) for ENSG.

ADUS screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas ENSG trades at 20.1x Forward P/E, 26.3x Trailing P/E, 1.40x PEG, and 2.2x EV/Revenue (3.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus ENSG (17.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, ENSG carries 99.5% implied volatility (62nd %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.12β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.